

Table S1. Clinicopathological characteristics of group C

Variable		<i>n</i> = 49	SARIFA- positive (<i>n</i> = 29)	SARIFA- negative (<i>n</i> = 20)	P-value
Median Age (years)		71 (61-77)	72 (61-78)	71 (61-77)	0.458
MedianLymph Node Harvest (n)		38 (29-49)	36 (28-53)	39 (30-49)	0.776
MedianPositive Lymph Nodes (n)		0 (0-2)	1 (0-4)	0 (0-1)	0.992
Sex					0.842
	female	20 (41%)	12 (41%)	8 (40%)	
	male	29 (59%)	17 (59%)	12 (60%)	
T status					0.042
	pT3	35 (71%)	12 (41%)	15 (75%)	
	pT4	14 (29%)	17 (59%)	5 (25%)	
Grading					0.700
	low grade	41 (84%)	25 (86%)	16 (80%)	
	high grade	8 (16%)	4 (14%)	4 (20%)	
Vascular invasion					0.234
	negative	36 (73%)	19 (66%)	17 (85%)	
	positive	13 (27%)	10 (34%)	3 (15%)	
Lymphatic invasion					0.512
	negative	37 (76%)	23 (79%)	14 (70%)	
	positive	12 (24%)	6 (21%)	6 (30%)	
Location					0.842
	right	28 (57%)	12 (41%)	8 (40%)	
	left	21 (43%)	17 (59%)	12 (60%)	
MMS					1.000
	stabe	40 (95%)*	25 (96%)	16 (94%)	
	instable	2 (5%)*	1 (4%)	1 (6%)	
Adjuvant Therapy					0.272
	no	23 (47%)	13 (45%)	13 (65%)	
	yes	26 (53%)	16 (55%)	7 (35%)	
Death					0.496
	no	39 (80%)	22 (76%)	13 (65%)	
	yes	10 (20%)	7 (24%)	3 (15%)	

Table S2. Spearman Corelation of morphological biomarkers

	Tumor budding	PDC	SG	Jass
SARIFA	0.267	0.281	0.148	0.217
	0.0633	0.0503	0.308	0.134
	49	49	49	49
Tumor budding		0.710	0.250	0.253
		0.000000200	0.0832	0.0788
		49	49	49
PDC			0.0671	0.102
			0.645	0.482
			49	49

SG	0.231
	0.110
	49
Jass	

Legend: SARIFA, Stroma AReactive Invasion Front Areas; PDC, poorly differentiated clusters; SG, Stroma Grading ; Jass, Infiltration Classifiacion according to Jass

Table S3. Subgroup analyses of SARIFA in UICC stage II vs. III

		Group A + B			
Overall survival		HR	95%CI	p value	p value (log rank)
	Stage II (n=340)	1.299	0.696 – 2.424	0.411	0.409
	Stage III (n=140)	1.707	1.083 – 2.692	0.021	0.020
Colon-cancer-specific survival					
	Stage II (n=340)	0.832	0.188 – 3.675	0.808	0.808
	Stage III (n=140)	2.432	1.196 – 4.948	0.014	0.011
Metastasis-free survival					
	Stage II (n=340)	1.172	0.487-2.817	0.724	0.723
	Stage III (n=140)	1.916	1.168-3.144	0.010	0.009

HR: Hazard Ratio of SARIFA positive cases - Reference: SARIFA negative cases; CI: Confidence intervall (95%)




Figure S1 Percentage of high-grade features of morphological biomarkers depending on the SRAIFA grading in group C